Neuroinflammation in Alzheimer's disease: potential targets for disease-modifying drugs.
Hüll
M
M
Department of Psychiatry, University of Freiburg, Medical School, Hauptstr. 5, 79104 Freiburg, Germany. michael_huell@psyallg.ukl.uni-freiburg.de
Hampel
H
H
D000209:Acute-Phase Proteins / Q000378:metabolism; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000276:immunology*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D002490:Central Nervous System / Q000276:immunology; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D006801:Humans; D007527:Isoenzymes / Q000096:biosynthesis; D008565:Membrane Proteins; D051379:Mice; D017628:Microglia / Q000502:physiology; D008954:Models, Biological; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis; D014612:Vaccines / Q000627:therapeutic use
D000209:Acute-Phase Proteins; D000893:Anti-Inflammatory Agents; D016207:Cytokines; D007527:Isoenzymes; D008565:Membrane Proteins; D014612:Vaccines; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; C496512:Ptgs1 protein, mouse